EU/3/11/909

About

On 27 September 2011, orphan designation (EU/3/11/909) was granted by the European Commission to Actelion Registration Limited, United Kingdom, for macitentan for the treatment of pulmonary arterial hypertension.

Macitentan has been authorised in the EU as Opsumit since 20 December 2013.

The sponsorship was transferred to Janssen-Cilag International N.V., Belgium, in September 2018.

Key facts

Active substance
Macitentan
Medicine name
Opsumit
Disease / condition
Treatment of pulmonary arterial hypertension
Date of first decision
27/09/2011
Outcome
Positive
EU designation number
EU/3/11/909

Review of designation

During its meeting of 5-6 November 2013, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EU/3/11/909 for Opsumit (macitentan) as an orphan medicinal product for the treatment of pulmonary arterial hypertension. The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other satisfactory methods of treatment. As other methods of treatment for patients with this condition are authorised in the European Union (EU), the COMP also looked at the significant benefit of the product over existing treatments. The COMP recommended that the orphan designation of the medicine be maintained.

Sponsor's contact details

Janssen-Cilag International N.V.
Turnhoutseweg, 30
2340 Beerse
Belgium
Tel. +32 146 031 89
E-mail: https://www.janssen.com/emea/contact-us

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating